オプションチェーンは、Portage Biotechの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Portage Biotechの市場センチメントを評価します。.

Portage Biotech (NASDAQ:PRTG) 株価情報, オプションチェーン

Portage Biotech

Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.

Portage Biotech Inc

Nucor Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) reported first-quarter financial results after the market close on Monday. Here&#8217;s what you need to know <a href="https://www.benzinga.com/pressreleases/25/04/n45053335/nucor-reports-results-for-the-first-quarter-of-2025">from the report</a>.
<ul>
<li>Q1 Revenue: $7.83 billion, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $7.23 billion</li>
</ul>
<ul>
<li>Q1 Adjusted EPS: 77 cents, versus estimates of 64 cents</li>
</ul>
Total revenue was down 4% on a year-over-year basis. The steel manufacturer said it shipped approximately 6.83 million tons to outside customers during the quarter. Average sales price per ton decreased&nbsp;12%&nbsp;year-over-year, while total steel mill shipments increased 10% year-over-year.
Nucor repurchased approximately 2.3 million shares at an average price of $133.17 per share in the quarter. The steel company had $806 million remaining on its buyback as of April 5. Nucor ended the quarter with $4.06 billion in cash, cash equivalents and short-term investments on hand.&nbsp;
&#8220;Despite recent financial market volatility, Nucor is seeing solid demand for the steel and steel products we manufacture. Our healthy balance sheet and diverse product portfolio position us well, even in uncertain times,&#8221; said&nbsp;Leon Topalian, chair, president and CEO of Nucor.
See Also: <a href="https://www.benzinga.com/news/management/25/04/45053723/nxp-semiconductors-reports-q1-earnings-very-uncertain-operating-environment-tied-to-tariffs-ceo-transition-shares-fall">NXP Semiconductors Reports Q1 Earnings: &#8216;Very Uncertain&#8217; Operating Environment Tied To Tariffs, CEO Transition, Shares Fall</a>
Outlook: Nucor expects second-quarter earnings to increase across all three operating segments (steel mills, steel products and raw materials) compared to the first quarter. 
The stock reaction is somewhat muted, likely due to the company already reporting preliminary results for the quarter in March. Executives will further discuss the quarter on a call with investors and analysts Tuesday morning at 10 a.m. ET.
NUE Price Action: <a href="http://benzinga.com/quote/nue" target="_blank" rel="noreferrer noopener">Nucor shares</a> were up 1.02% after-hours, trading at $117.76 at the time of publication Monday, per <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: saweang.w/Shutterstock.

Earnings

News

Guidance

Commodities

After-Hours Center

Movers

Nucor Q1 Earnings: Revenue Beat, EPS Beat, 'Solid' Steel Demand And More

Travelzoo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TZOO#NASDAQ">TZOO</a>) is preparing to release its quarterly earnings on Tuesday, 2025-04-29. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Travelzoo to report an earnings per share (EPS) of $0.25.
Investors in Travelzoo are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Overview of Past Earnings</h3>
In the previous earnings release, the company missed EPS by $0.04, leading to a 10.38% increase in the share price the following trading session.
Here's a look at Travelzoo's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.30</td>
<td>0.20</td>
<td>0.22</td>
<td>0.30</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.26</td>
<td>0.26</td>
<td>0.23</td>
<td>0.31</td>
</tr>
<tr>
<td>Price Change %</td>
<td>10.0%</td>
<td>3.0%</td>
<td>7.000000000000001%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745874187_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Travelzoo were trading at $13.32 as of April 25. Over the last 52-week period, shares are up 40.52%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/TZOO/earnings">To track all earnings releases for Travelzoo visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TZOO

A Peek at Travelzoo's Future Earnings

Intrusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement.
Analysts estimate that Intrusion will report an earnings per share (EPS) of $-0.11. 
Anticipation surrounds Intrusion's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Historical Earnings Performance</h3>
The company's EPS missed by $0.15 in the last quarter, leading to a 21.3% drop in the share price on the following day.
Here's a look at Intrusion's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.21</td>
<td>-0.42</td>
<td>-0.55</td>
<td>-1.20</td>
<td>-2.2</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.36</td>
<td>-0.35</td>
<td>-0.53</td>
<td>-0.94</td>
<td>-1.8</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-21.0%</td>
<td>-15.0%</td>
<td>19.0%</td>
<td>-26.0%</td>
<td>-9.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745874178_0.png" alt="eps graph" />
<h3>Performance of Intrusion Shares</h3>
Shares of Intrusion were trading at $1.26 as of April 25. Over the last 52-week period, shares are down 21.84%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/INTZ/earnings">To track all earnings releases for Intrusion visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

INTZ

A Peek at Intrusion's Future Earnings

Rocky Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKY#NASDAQ">RCKY</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement.
Analysts estimate that Rocky Brands will report an earnings per share (EPS) of $0.52. 
Investors in Rocky Brands are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Performance in Previous Earnings</h3>
The company's EPS missed by $0.03 in the last quarter, leading to a 10.9% drop in the share price on the following day.
Here's a look at Rocky Brands's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.22</td>
<td>0.98</td>
<td>0.09</td>
<td>0.02</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.19</td>
<td>0.77</td>
<td>0.17</td>
<td>0.41</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-11.0%</td>
<td>-27.0%</td>
<td>-2.0%</td>
<td>28.000000000000004%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745874157_0.png" alt="eps graph" />
<h3>Tracking Rocky Brands's Stock Performance</h3>
Shares of Rocky Brands were trading at $13.7 as of April 25. Over the last 52-week period, shares are down 47.77%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/RCKY/earnings">To track all earnings releases for Rocky Brands visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RCKY

Rocky Brands Earnings Preview

Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Zynex to report an earnings per share (EPS) of $-0.24.
The announcement from Zynex is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Past Earnings Performance</h3>
The company's EPS missed by $0.11 in the last quarter, leading to a 51.29% drop in the share price on the following day.
Here's a look at Zynex's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.09</td>
<td>0.06</td>
<td>0.08</td>
<td>0.03</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.02</td>
<td>0.07</td>
<td>0.04</td>
<td>0</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-51.0%</td>
<td>6.0%</td>
<td>-12.0%</td>
<td>7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745874149_0.png" alt="eps graph" />
<h3>Zynex Share Price Analysis</h3>
Shares of Zynex were trading at $2.41 as of April 25. Over the last 52-week period, shares are down 79.54%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<h3>Analyst Opinions on Zynex</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Zynex.
Zynex has received a total of 2 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $10.25, the consensus suggests a potential 325.31% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
The below comparison of the analyst ratings and average 1-year price targets of Fractyl Health, Hyperfine and CytoSorbents, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Fractyl Health, with an average 1-year price target of $11.0, suggesting a potential 356.43% upside.</li>
<li>Analysts currently favor an Buy trajectory for Hyperfine, with an average 1-year price target of $1.33, suggesting a potential 44.81% downside.</li>
<li>Analysts currently favor an Buy trajectory for CytoSorbents, with an average 1-year price target of $7.0, suggesting a potential 190.46% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
The peer analysis summary outlines pivotal metrics for Fractyl Health, Hyperfine and CytoSorbents, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zynex</td>
<td>Buy</td>
<td>-2.77%</td>
<td>$35.99M</td>
<td>-1.72%</td>
</tr>
<tr>
<td>Fractyl Health</td>
<td>Buy</td>
<td>-57.14%</td>
<td>$3K</td>
<td>-63.42%</td>
</tr>
<tr>
<td>Hyperfine</td>
<td>Buy</td>
<td>-13.59%</td>
<td>$826K</td>
<td>-19.36%</td>
</tr>
<tr>
<td>CytoSorbents</td>
<td>Buy</td>
<td>24.52%</td>
<td>$9.40M</td>
<td>-65.41%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Zynex ranks at the top for Revenue Growth and Gross Profit among its peers. However, it ranks at the bottom for Return on Equity. Overall, Zynex is performing well in terms of revenue and profit compared to its peers, but its return on equity is lower in comparison.
<h3>About Zynex</h3>
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company operates business as one operating segment which includes two revenue types: Devices and Supplies. Its markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.
<h3>Financial Milestones: Zynex's Journey</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Zynex's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -2.77%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Zynex's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.34% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Zynex's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.72% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Zynex's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.5% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.07, caution is advised due to increased financial risk.
<a href="https://www.benzinga.com/quote/ZYXI/earnings">To track all earnings releases for Zynex visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ZYXI

Earnings Outlook For Zynex

Stem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement.
Analysts estimate that Stem will report an earnings per share (EPS) of $-0.14. 
The announcement from Stem is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings History Snapshot</h3>
In the previous earnings release, the company missed EPS by $0.13, leading to a 13.07% increase in the share price the following trading session.
Here's a look at Stem's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.18</td>
<td>-0.21</td>
<td>-0.22</td>
<td>-0.21</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.31</td>
<td>-0.27</td>
<td>-0.22</td>
<td>-0.46</td>
</tr>
<tr>
<td>Price Change %</td>
<td>13.0%</td>
<td>-22.0%</td>
<td>-41.0%</td>
<td>-28.999999999999996%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745874127_0.png" alt="eps graph" />
<h3>Tracking Stem's Stock Performance</h3>
Shares of Stem were trading at $0.4154 as of April 25. Over the last 52-week period, shares are down 77.23%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/STEM/earnings">To track all earnings releases for Stem visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

STEM

A Preview Of Stem's Earnings

Northeast Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBN#NASDAQ">NBN</a>) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Northeast Bank to report an earnings per share (EPS) of $2.78.
The market awaits Northeast Bank's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Historical Earnings Performance</h3>
In the previous earnings release, the company beat EPS by $0.17, leading to a 3.03% increase in the share price the following trading session.
Here's a look at Northeast Bank's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.57</td>
<td>1.77</td>
<td>1.79</td>
<td>1.72</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.74</td>
<td>2.11</td>
<td>1.91</td>
<td>1.83</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>3.0%</td>
<td>1.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745874116_0.png" alt="eps graph" />
<h3>Market Performance of Northeast Bank's Stock</h3>
Shares of Northeast Bank were trading at $91.1 as of April 25. Over the last 52-week period, shares are up 78.67%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/NBN/earnings">To track all earnings releases for Northeast Bank visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Uncovering Potential: Northeast Bank's Earnings Preview

Global Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIC#NYSE">GIC</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement.
Analysts estimate that Global Industrial will report an earnings per share (EPS) of $0.20. 
Investors in Global Industrial are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Performance in Previous Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.01, leading to a 0.41% drop in the share price on the subsequent day.
Here's a look at Global Industrial's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.28</td>
<td>0.58</td>
<td>0.51</td>
<td>0.38</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.27</td>
<td>0.44</td>
<td>0.52</td>
<td>0.34</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-0.0%</td>
<td>-21.0%</td>
<td>-3.0%</td>
<td>-10.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745874106_0.png" alt="eps graph" />
<h3>Global Industrial Share Price Analysis</h3>
Shares of Global Industrial were trading at $22.12 as of April 25. Over the last 52-week period, shares are down 42.77%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/GIC/earnings">To track all earnings releases for Global Industrial visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Examining the Future: Global Industrial's Earnings Outlook

LSB Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LXU#NYSE">LXU</a>) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate LSB Industries to report an earnings per share (EPS) of $0.04.
Investors in LSB Industries are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Historical Earnings Performance</h3>
The company's EPS missed by $0.04 in the last quarter, leading to a 4.03% drop in the share price on the following day.
Here's a look at LSB Industries's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.11</td>
<td>-0.07</td>
<td>0.11</td>
<td>0.05</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.07</td>
<td>-0.11</td>
<td>0.13</td>
<td>0.08</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>-3.0%</td>
<td>3.0%</td>
<td>13.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745874097_0.png" alt="eps graph" />
<h3>Tracking LSB Industries's Stock Performance</h3>
Shares of LSB Industries were trading at $5.65 as of April 25. Over the last 52-week period, shares are down 36.67%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Insights on LSB Industries</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on LSB Industries.
A total of 1 analyst ratings have been received for LSB Industries, with the consensus rating being Buy. The average one-year price target stands at $8.0, suggesting a potential 41.59% upside.
<h3>Understanding Analyst Ratings Among Peers</h3>
The below comparison of the analyst ratings and average 1-year price targets of Intrepid Potash, Aspen Aerogels and Koppers Hldgs, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Sell trajectory for Intrepid Potash, with an average 1-year price target of $20.0, suggesting a potential 253.98% upside.</li>
<li>Analysts currently favor an Buy trajectory for Aspen Aerogels, with an average 1-year price target of $16.8, suggesting a potential 197.35% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Koppers Hldgs, with an average 1-year price target of $64.0, suggesting a potential 1032.74% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
The peer analysis summary offers a detailed examination of key metrics for Intrepid Potash, Aspen Aerogels and Koppers Hldgs, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>LSB Industries</td>
<td>Buy</td>
<td>1.73%</td>
<td>$6.05M</td>
<td>-1.85%</td>
</tr>
<tr>
<td>Intrepid Potash</td>
<td>Sell</td>
<td>-1.52%</td>
<td>$7.29M</td>
<td>-35.85%</td>
</tr>
<tr>
<td>Aspen Aerogels</td>
<td>Buy</td>
<td>46.15%</td>
<td>$47.13M</td>
<td>2.02%</td>
</tr>
<tr>
<td>Koppers Hldgs</td>
<td>Outperform</td>
<td>-7.05%</td>
<td>$83.60M</td>
<td>-2.00%</td>
</tr>
</tbody>
</table>

Key Takeaway:
LSB Industries ranks at the bottom for Revenue Growth and Gross Profit among its peers. It is at the top for Consensus rating and Return on Equity.
<h3>Unveiling the Story Behind LSB Industries</h3>
LSB Industries Inc is engaged in the manufacturing and sale of chemical products in the United States. The company manufactures and sells chemical products for the agricultural and industrial sectors. Its products include ammonia, fertilizer grade ammonium nitrate (AN and HDAN), and urea ammonia nitrate (UAN) for agricultural applications; high purity and commercial grade ammonia, sulfuric acids, concentrated, blended, and regular nitric acid, mixed nitrating acids, carbon dioxide, and diesel exhaust fluid for industrial applications; and industrial grade AN (LDAN) and AN solutions for mining applications. Its products are sold through distributors and directly to end customers throughout the United States and other parts of North America.
<h3>Unraveling the Financial Story of LSB Industries</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining LSB Industries's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1.73% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Materials sector.
Net Margin: LSB Industries's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -6.78%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): LSB Industries's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.85% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): LSB Industries's ROA stands out, surpassing industry averages. With an impressive ROA of -0.77%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 1.06, LSB Industries faces challenges in effectively managing its debt levels, indicating potential financial strain.
<a href="https://www.benzinga.com/quote/LXU/earnings">To track all earnings releases for LSB Industries visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Preview Of LSB Industries's Earnings

CECO Environmental (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CECO#NASDAQ">CECO</a>) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate CECO Environmental to report an earnings per share (EPS) of $0.09.
Anticipation surrounds CECO Environmental's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS beat by $0.04, leading to a 0.04% increase in the share price on the subsequent day.
Here's a look at CECO Environmental's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.23</td>
<td>0.19</td>
<td>0.16</td>
<td>0.11</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.27</td>
<td>0.14</td>
<td>0.20</td>
<td>0.11</td>
</tr>
<tr>
<td>Price Change %</td>
<td>0.0%</td>
<td>9.0%</td>
<td>4.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745874088_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of CECO Environmental were trading at $19.93 as of April 25. Over the last 52-week period, shares are down 11.19%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/CECO/earnings">To track all earnings releases for CECO Environmental visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CECO

CECO Environmental's Earnings Outlook

Stepan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCL#NYSE">SCL</a>) is preparing to release its quarterly earnings on Tuesday, 2025-04-29. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Stepan to report an earnings per share (EPS) of $0.60.
Anticipation surrounds Stepan's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Historical Earnings Performance</h3>
The company's EPS missed by $0.21 in the last quarter, leading to a 2.21% increase in the share price on the following day.
Here's a look at Stepan's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.33</td>
<td>0.65</td>
<td>0.67</td>
<td>0.35</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.12</td>
<td>1.03</td>
<td>0.41</td>
<td>0.64</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.0%</td>
<td>-3.0%</td>
<td>-5.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745874081_0.png" alt="eps graph" />
<h3>Tracking Stepan's Stock Performance</h3>
Shares of Stepan were trading at $48.24 as of April 25. Over the last 52-week period, shares are down 41.93%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/SCL/earnings">To track all earnings releases for Stepan visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights Ahead: Stepan's Quarterly Earnings

Camping World Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWH#NYSE">CWH</a>) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Camping World Holdings to report an earnings per share (EPS) of $-0.21.
The announcement from Camping World Holdings is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.07, which was followed by a 0.24% drop in the share price the next day.
Here's a look at Camping World Holdings's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.54</td>
<td>0.11</td>
<td>0.50</td>
<td>-0.35</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.47</td>
<td>0.13</td>
<td>0.38</td>
<td>-0.40</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-0.0%</td>
<td>7.000000000000001%</td>
<td>-4.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745874074_0.png" alt="eps graph" />
<h3>Tracking Camping World Holdings's Stock Performance</h3>
Shares of Camping World Holdings were trading at $13.83 as of April 25. Over the last 52-week period, shares are down 32.12%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Views on Camping World Holdings</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Camping World Holdings.
The consensus rating for Camping World Holdings is Buy, based on 5 analyst ratings. With an average one-year price target of $20.0, there's a potential 44.61% upside.
<h3>Peer Ratings Overview</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of and Camping World Holdings, three key industry players, offering insights into their relative performance expectations and market positioning.
<h3>Comprehensive Peer Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for and Camping World Holdings, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Camping World Holdings</td>
<td>Buy</td>
<td>8.58%</td>
<td>$376.92M</td>
<td>-14.55%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Camping World Holdings ranks at the bottom for Revenue Growth among its peers. It also ranks at the bottom for Gross Profit. However, it ranks at the top for Return on Equity. Overall, Camping World Holdings is positioned in the middle compared to its peers based on the provided metrics.
<h3>All You Need to Know About Camping World Holdings</h3>
Camping World Holdings Inc is a retailer of RVs and related products and services. The company has two reportable segments; the Good Sam Services and Plans segment, which includes the sale of emergency roadside assistance plans; commissions on property and casualty insurance programs; travel assist programs; extended vehicle service contracts; vehicle financing and refinancing assistance; consumer shows and events; and consumer publications and directories; and the RV and Outdoor Retail segment, which generates maximum revenue and includes the sale of new and used RVs; commissions on the finance and insurance contracts related to the sale of RVs; the sale of RV service and collision work; the sale of RV parts, accessories, business to business distribution of RV furniture, etc.
<h3>Key Indicators: Camping World Holdings's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Camping World Holdings's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 8.58%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Camping World Holdings's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -2.62%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Camping World Holdings's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -14.55%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Camping World Holdings's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.66%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Camping World Holdings's debt-to-equity ratio stands notably higher than the industry average, reaching 11.15. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<a href="https://www.benzinga.com/quote/CWH/earnings">To track all earnings releases for Camping World Holdings visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: Camping World Holdings

In the last three months, 12 analysts have published ratings on Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>), offering a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $129.67, a high estimate of $150.00, and a low estimate of $100.00. Marking an increase of 0.44%, the current average surpasses the previous average price target of $129.10. 
<img src="https://www.benzinga.com/files/images/story/2025/1745874059_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Blueprint Medicines. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;------------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Lowers &#x7C;Buy &#x7C; $130.00&#x7C;$133.00 &#x7C; 
&#x7C;David Nierengarten &#x7C;Wedbush &#x7C;Maintains &#x7C;Outperform &#x7C; $128.00&#x7C;$128.00 &#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $133.00&#x7C;$133.00 &#x7C; 
&#x7C;Judah Frommer &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $100.00&#x7C;$120.00 &#x7C; 
&#x7C;Michael Yee &#x7C;Jefferies &#x7C;Announces &#x7C;Buy &#x7C; $135.00&#x7C;- &#x7C; 
&#x7C;Louise Chen &#x7C;Scotiabank &#x7C;Announces &#x7C;Sector Outperform&#x7C; $150.00&#x7C;- &#x7C; 
&#x7C;Reni Benjamin &#x7C;Citizens Capital Markets&#x7C;Maintains &#x7C;Market Outperform&#x7C; $125.00&#x7C;$125.00 &#x7C; 
&#x7C;Reni Benjamin &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $125.00&#x7C;$125.00 &#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $133.00&#x7C;$133.00 &#x7C; 
&#x7C;Andrew Fein &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $135.00&#x7C;$135.00 &#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $133.00&#x7C;$133.00 &#x7C; 
&#x7C;Brian Cheng &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $129.00&#x7C;$126.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Blueprint Medicines. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Blueprint Medicines compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Blueprint Medicines's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Blueprint Medicines's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BPMC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Blueprint Medicines analyst ratings.</a>
<h2>About Blueprint Medicines</h2>
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.
<h3>Breaking Down Blueprint Medicines's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Blueprint Medicines's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 103.41%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Blueprint Medicines's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -34.13%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Blueprint Medicines's ROE excels beyond industry benchmarks, reaching -16.33%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Blueprint Medicines's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -4.2%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Blueprint Medicines's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.57, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

BPMC

What Analysts Are Saying About Blueprint Medicines Stock

Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $225.0, with a high estimate of $245.00 and a low estimate of $215.00. This upward trend is evident, with the current average reflecting a 4.07% increase from the previous average price target of $216.20.
<img src="https://www.benzinga.com/files/images/story/2025/1745874052_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Krystal Biotech's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Joseph Pantginis &#x7C;HC Wainwright &amp; Co. &#x7C;Raises &#x7C;Buy &#x7C; $240.00&#x7C;$221.00 &#x7C; 
&#x7C;Roger Song &#x7C;Jefferies &#x7C;Announces &#x7C;Buy &#x7C; $245.00&#x7C;- &#x7C; 
&#x7C;Joseph Pantginis &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $221.00&#x7C;$221.00 &#x7C; 
&#x7C;Yigal Nochomovitz &#x7C;Citigroup &#x7C;Raises &#x7C;Neutral &#x7C; $215.00&#x7C;$206.00 &#x7C; 
&#x7C;Josh Schimmer &#x7C;Cantor Fitzgerald &#x7C;Announces &#x7C;Overweight &#x7C; $215.00&#x7C;- &#x7C; 
&#x7C;Geulah Livshits &#x7C;Chardan Capital &#x7C;Raises &#x7C;Buy &#x7C; $218.00&#x7C;$212.00 &#x7C; 
&#x7C;Joseph Pantginis &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $221.00&#x7C;$221.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Krystal Biotech. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Krystal Biotech compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Krystal Biotech's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Krystal Biotech's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/KRYS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Krystal Biotech analyst ratings.</a>
<h2>Get to Know Krystal Biotech Better</h2>
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
<h3>Krystal Biotech: Financial Performance Dissected</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Over the 3M period, Krystal Biotech showcased positive performance, achieving a revenue growth rate of 116.26% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Krystal Biotech's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 49.9%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Krystal Biotech's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.96%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Krystal Biotech's ROA stands out, surpassing industry averages. With an impressive ROA of 4.46%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Krystal Biotech's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KRYS

Demystifying Krystal Biotech: Insights From 7 Analyst Reviews

Management

Sphere 3D Enters Amended Employment Agreement With Kurt Kalbfleisch; Under Agreement Kurt Kalbfleisch To Serve As CFO; Under Agreement, Kalbfleisch To Serve As Interim CEO During The Period Where No Replacement CEO Is Appointed

In the last three months, 5 analysts have published ratings on Apollo Comml Real Est (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARI#NYSE">ARI</a>), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Apollo Comml Real Est and provided 12-month price targets. The average target is $9.2, accompanied by a high estimate of $10.00 and a low estimate of $8.00. A decline of 1.08% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1745874039_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of Apollo Comml Real Est by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;-----------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Richard Shane &#x7C;JP Morgan &#x7C;Raises &#x7C;Neutral &#x7C; $9.00&#x7C;$8.00 &#x7C; 
&#x7C;Douglas Harter &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $9.00&#x7C;$10.00 &#x7C; 
&#x7C;Richard Shane &#x7C;JP Morgan &#x7C;Lowers &#x7C;Neutral &#x7C; $8.00&#x7C;$9.50 &#x7C; 
&#x7C;Jade Rahmani &#x7C;Keefe, Bruyette &amp; Woods&#x7C;Maintains &#x7C;Outperform &#x7C; $10.00&#x7C;$10.00 &#x7C; 
&#x7C;Douglas Harter &#x7C;UBS &#x7C;Raises &#x7C;Neutral &#x7C; $10.00&#x7C;$9.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Apollo Comml Real Est. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Apollo Comml Real Est compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Apollo Comml Real Est's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Apollo Comml Real Est's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ARI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Apollo Comml Real Est analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Apollo Comml Real Est: A Closer Look</h2>
Apollo Commercial Real Estate Finance Inc is a real estate investment trust that primarily originates, invests in, acquires, and manages commercial first-mortgage loans, subordinate financings, commercial mortgage-backed securities, and other real estate-related debt investments. The subordinate loans and first-mortgage loans account for the vast majority of the portfolio on a cost basis. Property types include residential, retail, healthcare, office, mixed-use, hotel, industrial, multifamily, securities, and other, with residential properties and hotels representing the highest property value. More than a third of the properties are located in New York City, with the other properties located across other regions of the United States, as well as other countries.
<h3>A Deep Dive into Apollo Comml Real Est's Financials</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Apollo Comml Real Est's revenue growth over a period of 3M has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -6.58%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Apollo Comml Real Est's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 47.07%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Apollo Comml Real Est's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.96% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.42%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 3.41, Apollo Comml Real Est adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 5 Analysts Discuss Apollo Comml Real Est Stock

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Pebblebrook Hotel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEB#NYSE">PEB</a>) in the last three months.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $12.56, a high estimate of $13.25, and a low estimate of $11.00. Highlighting a 18.34% decrease, the current average has fallen from the previous average price target of $15.38. 
<img src="https://www.benzinga.com/files/images/story/2025/1745874031_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Pebblebrook Hotel by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Richard Hightower &#x7C;Evercore ISI Group &#x7C;Lowers &#x7C;In-Line &#x7C; $11.00&#x7C;$15.00 &#x7C; 
&#x7C;Simon Yarmak &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $13.25&#x7C;$16.50 &#x7C; 
&#x7C;Dori Kesten &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $13.00&#x7C;$16.00 &#x7C; 
&#x7C;Gregory Miller &#x7C;Truist Securities &#x7C;Lowers &#x7C;Hold &#x7C; $13.00&#x7C;$14.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Pebblebrook Hotel. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Pebblebrook Hotel compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Pebblebrook Hotel's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Pebblebrook Hotel's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PEB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Pebblebrook Hotel analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Pebblebrook Hotel Better</h2>
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,933 rooms across 46 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.
<h3>Pebblebrook Hotel: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Pebblebrook Hotel's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1.05% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Real Estate sector.
Net Margin: Pebblebrook Hotel's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -18.08%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -2.24%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Pebblebrook Hotel's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -1.07%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Pebblebrook Hotel's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.95.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 4 Analysts Discuss Pebblebrook Hotel Stock

6 analysts have expressed a variety of opinions on SpringWorks Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for SpringWorks Therapeutics, presenting an average target of $68.5, a high estimate of $77.00, and a low estimate of $47.00. Observing a downward trend, the current average is 2.6% lower than the prior average price target of $70.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1745874023_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive SpringWorks Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Peter Lawson &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $47.00&#x7C;$63.00 &#x7C; 
&#x7C;Robert Burns &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $74.00&#x7C;$74.00 &#x7C; 
&#x7C;Robert Burns &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $74.00&#x7C;$74.00 &#x7C; 
&#x7C;David Nierengarten &#x7C;Wedbush &#x7C;Maintains &#x7C;Outperform &#x7C; $77.00&#x7C;$77.00 &#x7C; 
&#x7C;Cory Kasimov &#x7C;Evercore ISI Group &#x7C;Raises &#x7C;Outperform &#x7C; $65.00&#x7C;$60.00 &#x7C; 
&#x7C;Robert Burns &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $74.00&#x7C;$74.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to SpringWorks Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of SpringWorks Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of SpringWorks Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of SpringWorks Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SWTX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on SpringWorks Therapeutics analyst ratings.</a>
<h2>All You Need to Know About SpringWorks Therapeutics</h2>
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.
<h3>Unraveling the Financial Story of SpringWorks Therapeutics</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: SpringWorks Therapeutics's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 1029.96%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -125.59%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): SpringWorks Therapeutics's ROE excels beyond industry benchmarks, reaching -15.25%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): SpringWorks Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -12.92%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.02.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SWTX

Analyst Expectations For SpringWorks Therapeutics's Future

Looking into the current session, Entergy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>) shares are trading at $84.60, after a 0.01% drop. Over the past month, the stock fell by 0.67%, but over the past year, it actually increased by 61.25%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1745874017_0.png" alt="Past Year Chart" />

<h3>Comparing Entergy P/E Against Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of 18.69 in the Electric Utilities industry, Entergy Inc. has a higher P/E ratio of 34.53. Shareholders might be inclined to think that Entergy Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1745874017_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

A Look Into Entergy Inc's Price Over Earnings

Canadian Pacific Kansas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CP#NYSE">CP</a>) has outperformed the market over the past 20 years by 4.16% on an annualized basis producing an average annual return of 12.19%. Currently, Canadian Pacific Kansas has a market capitalization of $67.08 billion. 
Buying $1000 In CP: If an investor had bought $1000 of CP stock 20 years ago, it would be worth $9,914.44 today based on a price of $71.84 for CP at the time of writing.
<h3>Canadian Pacific Kansas's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745874014_0_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Press Releases

Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024

Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter

Portage Biotech Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics, Ltd

General

Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company

Financing

Portage Biotech Announces Completion of $2.15 Million Private Financing

Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements

Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial

Health Care

Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

Emerging Tech Quartet – PRSO, LXRX, PRTG, RNAZ – Drive Breakthroughs Across Defense, Obesity, Oncology, and RNA Therapeutics

Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

LXRX

PRSO

PRTG

RNAZ

ABVC BioPharma

BioVie

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Equillium

Ernexa Therapeutics

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech

Geovax Labs

Imunon

IN8bio

Kairos Pharma

Moleculin Biotech

MEI Pharma

Marker Therapeutics

Minerva Neurosciences, Inc - Common Stock

Comments

Portage Biotech

Portage Biotech (PRTG) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル